Serum Thyroglobulin (Tg) assay by immunoradiometric methods (IRMA): comparison of concentrations obtained with Cisbio Bioassays vs Beckman Coulter kit in patients with differentiated thyroid cancer.
Article Sidebar
Downloads
Submit your own article
Register as an author to reserve your spot in the next issue of the Medical Research Archives.
Author RegistrationJoin the Society
The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.
Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.
MembershipMain Article Content
Abstract
Introduction: In clinical practice, Thyroglobulin is a tumor marker for the post-operative follow-up of differentiated thyroid cancer, provided that any thyroid residual remains are eliminated beforehand, either by simple total thyroidectomy, or most often supplemented by isotopic totalization with Iode131. The aim of this study were to compare serum Tg values measured with 02 kit manufacturers of immunoradiometric type (IRMA) and to evaluate their cost/effectiveness ratio.
Methods: We included patients followed for differentiated thyroid cancer operated and irradiated with Iodine 131 at the nuclear medicine department of Tlemcen University Hospital. Their serum Thyroglobulin was dosed in the laboratory of the department with the Tg-IRMA kit of Cisbio Bioassays taken in this study as «Gold standard» and the Tg-IRMA kit of Beckman Coulter.
Results: Ninety-nine (99) serums of patients with CDT were measured for Thyroglobulin. The correlation of the Thyroglobulin values obtained with the 02 kits is positive and significant (r= 0.98; p < 0.01). The equation of the regression line of Passing- Bablok is of type y = 0.7 x + 0 (with Y = Tg-IRMA Cisbio Bioassays and X = Tg-IRMA Beckman Coulter). The difference in the averages analyzed with the Bland-Altman diagram is = 0 (p > 0.05), indicating that there is no difference in the mean of Tg between the 02 kits. The analysis by ROC curve of the Tg-IRMA Beckman Coulter kit Thyroglobulin values at the threshold of 0.7 and 1 ng/mL finds respectively a sensitivity and a specificity of 100% and 93% with an area under the curve = 0.99.
Conclusion: There is a strong correlation between Thyroglobulin concentrations obtained with the 02 kits, so a budget reduction in the management of our patients with diffrentiated thyroid cancer is possible, in favor of the Tg-IRMA kit of Beckman Coulter with a good cost/ efficiency ratio.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Th yroid cancer incidence patterns in the United States by histologic type, 1996-2006. Thyroid. 2014;21:125-34. http://dx.doi. org/10.1089/thy.2010.0021.DOI:10.1089/thy.2010.0021
3.Prpić M, Franceschi M, Romić M, Jukić T, Kusić Z. THYROGLOBULIN AS A TUMOR MARKER IN DIFFERENTIATED THYROID CANCER - CLINICAL CONSIDERATIONS. Acta Clin Croat. 2018 Sep;57(3):518-527. DOI: 10.20471/acc.2018.57.03.16
4. Malthiéry Y, Lissitzky S. Primary structure of human thyroglobulin deduced from the sequence of its 8448-base complementary DNA. Eur J Biochem. 1987;165:491-8. DOI: 10.1111/j.1432-1033.1987.tb11466.x
5. Giovanella L, Ceriani L, Maffioli M. Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma. Head Neck. 2010;32:568-571. DOI: 10.1002/hed.21214
6. Gurleyik E, Dogan S. Accuracy of unstimulated Basal serum thyroglobulin levels in assessing the completeness of thyroidectomy. J Clin Med Res. 2014;6:369-373. DOI: 10.14740/jocmr1873w
7. Feldt-Rasmussen U, Profilis C, Colinet E, et al. (1996).Human thyroglobulin reference material (CRM 457).1st part: assessment of homogeneity, stability and immunoreactivity. PMID: 9092300
8. Sadouk, M., W. Schneider, et al., Comparison of diagnostic performance of three thyroglobulin assays in the monitoring of diferentiated thyroid carcinoma. 75th Annual Meeting of the ATA (abstract), 2003.
9. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL,Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer DOI: 10.1089/thy.2009.0110
10. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002;12:37 43. DOI: 10.1089/105072502753 451959
11. Giovanella L, Clark P, Chiovato L, Duntas LH, Elisei R, FeldtRasmussen U, et al. Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. Eur J Endocrinol 2014;171:R33–46. DOI: 10.1530/E JE-14-0148
12. Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, Gilbert J, Harrison B, Johnson SJ, Giles TE, Moss L, Lewington V, Newbold K, Taylor J, Thakker RV, Watkinson J, Williams GR; British Thyroid Association. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014 Jul;81 Suppl 1:1-122. DOI: 10.1111/cen.12515. PM ID: 24989897.
13. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid. 1999;9:435–441.patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167–214. DOI: 10.1089/thy.1999.9. 435
14. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. DOI: 10.1089/thy.2015.0020. PMID: 26462967; PMCID: PMC4739132.
15. Dunn JT. Clinical usefulness of serum thyroglobulin assays.In: Hamburger JI, editor. Diagnostic methods in clinical thyroidology. New York: Springer Verlag; 1989. p 127–157. https ://link. springer.com / chapter /10.1007 / 978-1-4612-3612-2_7
16. Schlumberger M, Pacini F, Wiersinga WM, et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004;151:539–548. DOI : 10.1530 /eje.0.1510539
17. Ignjatovic V., Matovic M., Vukomanovic V. Comparison of Thyroglobulin Concentrations Measured by Two Immunoradiometric Assay. Experimental and Applied Biomedical Research (EABR). 2020;21(2): 121-125. DOI:1 0.2478/sjecr-2018-0031
18. Stanojevic M, Savin S, Cvejic D, et al. (2009). Correlation of thyroglobulin concentrations measured by radio immuno assay and immunometric assay and the influence of thyroglobulin antibody. J Immuno assay Immunochem, 30:197-207. DOI: 10.108 0/15321810902782897
19. Schlumberger M, Hitzel A, Toubert ME, et al. (2007).Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab, 92:2487–2495. DOI: 10.1210/jc.2006-0723
20. Spencer, C. A., M. Takeuchi et al., Current status and performance goals for serum thyroglobulin assays. Clinical Chemistry, 1996. 42: 164-173. PMID: 8565221
21. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al. Guidelines committee, National academy of clinical biochemistry. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003 ;13 3-126. DOI: 10.108 9/105072503321086962.